STOCK TITAN

vVARDIS closes IPO at $18 per Class A share

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

vVARDIS Holding AG (VVVV) closed its initial public offering on November 16, 2026, of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. The company granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the IPO price to cover over-allotments.

The Zug-based Swiss healthcare company operates in the dental med-tech sector and offers non-invasive solutions for dental professionals under its Curodont brand. Its amended and restated articles of association became effective November 13, 2026.

IPO shares 9,722,223 Class A ordinary shares Initial public offering closed November 16, 2026
Public offering price $18.00 per share Initial public offering
Underwriter option shares Up to 1,458,333 Class A ordinary shares Additional shares available under a 30-day option to cover over-allotments
Underwriter option period 30 days Option to purchase additional Class A ordinary shares
initial public offering financial
"closed its initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
over-allotments financial
"to cover over-allotments"
An over-allotment is a temporary extra batch of shares that the underwriters of a stock offering are allowed to sell beyond the original amount, with the right to buy those shares back later. Think of it as spare tickets sold to meet demand and then reclaimed if needed to keep the market orderly; it helps stabilize the stock price after an offering and can affect short-term supply and potential dilution, which matters to investors tracking price and ownership stakes.
joint bookrunning managers financial
"acting as joint bookrunning managers for the offering"
Joint bookrunning managers are the lead banks that work together to organize and sell a company’s new stock or bond offering, running the order book that records investor interest. Think of them as co-event planners who set the price, allocate shares to buyers and may commit to buy any unsold portion; their experience and reputation shape demand, pricing fairness and how stable the security is after it starts trading.
registration statement regulatory
"A registration statement on Form F-1"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VVVV shares did vVARDIS offer in its IPO, and at what price?

vVARDIS offered 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. The offering closed on November 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of November 2026
 
Commission File Number: 001-43538
 
vVARDIS HOLDING AG
(Translation of registrant’s name into English)

Gubelstrasse 24
6300 Zug
Switzerland
+41 78 258 4860
(Address of principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F ☒ Form 40-F ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐





On November 16, 2026, vVARDIS Holding AG (the “Company”) closed its initial public offering (“IPO”) of 9,722,223 Class A ordinary shares.
 
In connection with the IPO, the Company’s amended and restated articles of association became effective on November 13, 2026, a copy of which is attached as Exhibit 3.1, and is incorporated by reference herein.
 
In connection with the IPO, the Company issued a press release on November 12, 2026, announcing pricing of the IPO. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

EXHIBIT INDEX

Exhibit
No.

Description
3.1

Amended and Restated Articles of Association
99.1

Press Release on Pricing of the Company’s Initial Public Offering
104

Cover Page Interactive Data File (embedded with the Inline XBRL document).


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

VVARDIS HOLDING AG
     
Date: November 16, 2026
By:
/s/ Haley Abivardi


Haley Abivardi


Co-Chief Executive Officer,


Co-Founder & Co-Chair




Exhibit 99.1


vVARDIS Announces Pricing of Initial Public Offering
 
ZUG, Switzerland – November 12, 2026 — vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.”
 
The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions.
 
Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners.
 
A registration statement on Form F-1 relating to the offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on November 12, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained when available, from the SEC’s website at www.sec.gov, or from Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 866-471-2526 or by email at prospectus-ny@ny.email.gs.com; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 866-803-9204 or by email at prospectus-eq_fi@jpmorganchase.com.
 
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
 
About vVARDIS
vVARDIS is a Swiss healthcare company in the dental med-tech sector headquartered in Zug, Switzerland that offers innovative, non-invasive solutions for dental professionals with the Curodont® brand of products. vVARDIS’ mission is to create a world where cavity treatment is drill-free, regenerative and accessible to all.


Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. These statements may include words such as “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “could,” “would,” “project,” “target,” “plan,” “expect,” “predict,” “potential” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions are intended to identify forward-looking statements. These forward-looking statements include any statements regarding the commencement of trading of vVARDIS’ Class A ordinary shares on NYSE. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under “Risk Factors” in vVARDIS’ registration statement on Form F-1, as amended, relating to the initial public offering. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the registration statement. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts:

Media
FGS Global
vVARDISMedia@fgsglobal.com

Investors
vVARDIS Investor Relations
Sayan Bhattacharya
sayan.bhattacharya@vvardis.com



Filing Exhibits & Attachments

2 documents

Keep reading